Bristol-Myers Squib Archives -

After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year,

NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

https://pharmaphorum.com/news/nice-changes-tack-on-nhs-use-of-bms-myelofibrosis-drug-inrebic/

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

https://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/

Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role

The future of real world evidence

https://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/

Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA

FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention use

https://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/

For the first time, FDA approves drug on the basis of biomarkers, rather than location.

Keytruda wins another first with approval based on biomarkers

https://pharmaphorum.com/news/merck-cancer-biomarkers-keytruda/

Bristol-Myers Squib